Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02088840
Other study ID # SIGNB-GITMO-AMCLI-Survey
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2014
Est. completion date April 2016

Study information

Verified date August 2021
Source Gruppo Italiano Trapianto di Midollo Osseo
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

All patients undergoing autologous or allogeneic stem cell transplant (SCT) for any underlying disease will be monitored for severe infections by gram negative bacteria (SIGNB) during the engraftment period. The follow up will be stopped at 4 months from the day of transplant. About 50 transplant centers will be involved in the study.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


See more »

Sponsors (1)

Lead Sponsor Collaborator
Gruppo Italiano Trapianto di Midollo Osseo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of each type of Severe Infections by Gram Negative Bacteria To estimate the incidence of each type of Severe Infections by Gram Negative Bacteria , in particular by antibiotic resistant isolates, documented during the engraftment period in patients submitted to autologous and allogeneic stem cell transplant. 4 months by stem cell transplant
Secondary incidence particularly of Severe Infections by Gram Negative Bacteria To assess the incidence of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in subgroups of patients undergoing autologous or allogeneic stem cell transplant. 4 months by stem cell transplant
Secondary risk factors To assess the risk factors of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in autologous and allogeneic Stem cell CT transplant 4 month by stem cell transplant
Secondary prognostic factors To assess the prognostic factors of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in autologous and allogeneic Stem cell CT transplant 4 month by stem cell transplant
Secondary overall mortality for SIGNB To assess the overall Severe Infections by Gram Negative Bacteria and attributable mortality at 3 months from the SIGNB 3 months from the Severe Infections by Gram Negative Bacteria
Secondary overall survival for SIGNB from transplant To assess the impact of SIGNB on the overall survival at 4 months from transplant in autologous and allogeneic Stem Cell Transplantation 4 months from transplant
Secondary susceptibility pattern to antimicrobials of microorganisms To evaluate the susceptibility pattern to antimicrobials of microorganisms causing Severe Infections by Gram Negative Bacteria with particular attention to enterobacteria with particular attention to the resistance phenotypes 4 month by stem cell transplant
Secondary antibacterial strategies To describe the antibacterial strategies (in prophylaxis and therapy) employed in the various centers and in the various categories of patients particularly for the management of antibiotic resistant enterobacteria 4 month by stem cell transplant
Secondary local strategy To evaluate the impact of a local strategy in the use of antibiotics on the epidemiology of Severe Infections by Gram Negative Bacteria 4 month by stem cell transplant
See also
  Status Clinical Trial Phase
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00177814 - Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Suspended NCT00563134 - A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult N/A
Active, not recruiting NCT05171257 - Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
Completed NCT03160040 - A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
Completed NCT02962934 - An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
Not yet recruiting NCT06135350 - Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV Phase 2
Enrolling by invitation NCT04055922 - Comparison of Solid Organ Transplant
Completed NCT00490477 - The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial Phase 3
Recruiting NCT04861922 - Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection Phase 3
Completed NCT01732250 - Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem Phase 4
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Recruiting NCT06086626 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants Phase 2
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Completed NCT02285075 - Temocillin Pharmacokinetic in Hemodialysis Phase 4
Completed NCT03182504 - A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants Phase 1
Not yet recruiting NCT04917380 - The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Completed NCT03397914 - Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections Phase 4
Recruiting NCT01600768 - Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients N/A